About Appili Therapeutics
Appili Therapeutics is a publicly listed company based in Halifax (Canada) founded in 2015, and was acquired by Aditx Therapeutics in April 2024. Appili Therapeutics has raised $15.53 million across 14 funding rounds from investors including Fujifilm, Aditx Therapeutics and United States Air Force Academy. The company has 7 employees. Appili Therapeutics offers products and services including LIKMEZ, ATI-1701, and ATI-1801. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified.
Company details
Developer of drugs to treat infectious diseases. The companys product API-1503 is a class of 30S ribosome targeting agents for Gram-negative bacterias, API-1501 is a formulation of metronidazole, TI-2307 is a broad spectrum anti-fungal, ATI-1701 is a Tularemia vaccine, and Avigan is a broad-spectrum antiviral and therapeutic for COVID-19.
- Headquarters Halifax, Canada
- Employees 7
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website appilitherapeutics.com
- Social LinkedIn X
- Acquired by Aditx Therapeutics (Apr 2024)
- Legal Name Appili Therapeutics Inc Class A
- Annual Revenue$175.23 K (USD)143.1as on Mar 31, 2026
- Net Profit-$3.04 M (USD)-61.57as on Mar 31, 2026
- EBITDA-$4.69 M (USD)32.97as on Mar 31, 2026
- Total Equity Funding$15.53M (USD)
in 14 rounds
- Latest Funding Round$532.66K (USD), Post-IPO
Nov 2025
- InvestorsFujifilm
& 6 more
- Employee Count7
- Acquired byAditx Therapeutics
(Apr 2024)
Products & Services of Appili Therapeutics
Appili Therapeutics offers a comprehensive portfolio of products and services, including LIKMEZ, ATI-1701, and ATI-1801.
Treats serious anaerobic and protozoal infections worldwide.
Potential vaccine against tularemia biothreat agent.
Addresses disfiguring skin infections globally.
Funding Insights of Appili Therapeutics
Appili Therapeutics has successfully raised a total of $15.53M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $532.66 thousand completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.53M
- Total Rounds 14
- Last Round Post-IPO — $532,661
- First Round $3.27M
(May 2016)
- Investors Count 6
Latest 10 of 14 funding rounds of Appili Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $532,661 | Post-IPO | – | – | – |
| Oct 2023 | $6.6M | Grant | – | – | |
| May 2023 | $7.3M | Grant | – | – | |
| Sep 2021 | $1M | Post-IPO | – | – | |
| Aug 2021 | $3.5M | Post-IPO | – | – | |
| Jun 2020 | $15.53M | Post-IPO | – | – | – |
| Apr 2019 | $357,511 | Debt – Conventional | – | – | – |
| Mar 2019 | $2.67M | Series A | – | – | – |
| Feb 2018 | $4.34M | Series A | – | – | |
| Nov 2017 | $1.2M | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Appili Therapeutics
Appili Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fujifilm, Aditx Therapeutics and United States Air Force Academy.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
The Lind Partners is based in New York, USA. | thelindpartners.com | New York, United States | ||
Multiple sectors are invested in by the venture capital firm. | 1934 | fujifilm.com | Minato, Japan | |
Delivers expert business strategy and technology consulting services to support organizational growth. | 2009 | investnovascotia.ca | Halifax, Canada | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Economic development in Atlantic Canada is supported by federal initiatives. | acoa-apeca.gc.ca | Moncton, Canada | ||
Offers academic, military, and athletic training for Air Force cadets. | 1954 | usafa.edu | Air Force Academy, United States | |
Immune monitoring solutions are provided to the medical community. | 2017 | aditxt.com | Loma Linda, United States |
Investor details for Appili Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Appili Therapeutics
11 people are tracked at Appili Therapeutics (6 in leadership, 4 in board & advisors, 1 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Carl Gelhaus | Director of Nonclinical Research | Leadership |
Don Cilla | President & CEO | Leadership |
Gary Nabors | Chief Development Officer | Leadership |
Kenneth Howling | Acting CFO | Leadership |
Art Baran | Director Of Product Management | Leadership |
Leona Saunders | Director, Regulatory Affairs | Leadership |
Brian Bloom | Board Member | Board & advisors |
Juergen Froehlich | Board Member | Board & advisors |
Theresa Matkovits | Lead Independent Board Director | Board & advisors |
Rochelle Stenzler | Board Member | Board & advisors |
Joanna Gore | Clinical Research Scientist | Team |
Complete people profiles for Appili Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Appili Therapeutics
Appili Therapeutics is a publicly listed company on the TSX with ticker symbol APLI in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Sep 2020
- Listed onTSX: APLI
- Listed entityAppili Therapeutics Inc Class A
- Exchange sectorHealth technology
- ISINCA03783R1073
- Share price0.01 CAD (-50% on the day) · 2026-10-02
- Market capitalisation661,831.00 CAD
- EPS (diluted, trailing year)-0.04 CAD
- Volume (last session)117,001
Financials of Appili Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 244,180 CAD | -4.2M CAD | -6.5M CAD |
| 2024 | 100,440 CAD | -2.6M CAD | -9.7M CAD |
| 2023 | 827,410 CAD | -3.8M CAD | -8.0M CAD |
| 2022 | 334,180 CAD | -9.2M CAD | -7.6M CAD |
| 2021 | 1.4M CAD | -25.1M CAD | -25.5M CAD |
Detailed financial statements for Appili Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Appili Therapeutics
5 dated milestones of Appili Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Appili Therapeutics is founded.
- Funding First funding round of $3.3M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Aditx Therapeutics.
- Funding Latest funding round, Post-IPO, of $533K.
Web traffic of Appili Therapeutics
The website of Appili Therapeutics (appilitherapeutics.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 180.8% vs previous month
Websites whose visitors overlap most with Appili Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| smartsti.com | 100% | 9.1K | #2,549,143 | View details | |
| abkbiomedical.com | 98% | 3.3K | #5,541,631 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Appili Therapeutics
Complete news archive for Appili Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Appili Therapeutics
Appili Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Appili Therapeutics is headquartered in Halifax, Canada. It is registered at Halifax, Nova Scotia, Canada.
Appili Therapeutics is a funded company, having raised a total of $15.53M across 14 funding rounds to date. The company's 1st funding round was a Grant of $1.2M, raised on May 2016.
Appili Therapeutics has 7 employees.
Annual revenue of Appili Therapeutics is $175.23K as on Mar 31, 2026.
Developer of drugs to treat infectious diseases. The companys product API-1503 is a class of 30S ribosome targeting agents for Gram-negative bacterias, API-1501 is a formulation of metronidazole, TI-2307 is a broad spectrum anti-fungal, ATI-1701 is a Tularemia vaccine, and Avigan is a broad-spectrum antiviral and therapeutic for COVID-19.
Appili Therapeutics offers LIKMEZ, ATI-1701, and ATI-1801.
Yes, Appili Therapeutics is publicly traded on TSX under the ticker symbol APLI.
Appili Therapeutics has 7 investors. Key investors include Fujifilm, Aditx Therapeutics, United States Air Force Academy, The Lind Partners, and Invest Nova Scotia.
Yes. Appili Therapeutics was acquired by Aditx Therapeutics in April 2024.